Preclinical Evaluation of the Novel BTK Inhibitor Acalabrutinib in Canine Models of B-Cell Non-Hodgkin LymphomaBonnie K. Harrington, William C. Kisseberth|PLoS ONE|2016Cited by 58
Sensitivity of osteosarcoma cells to HDAC inhibitor AR-42 mediated apoptosisSridhar Murahari, William C. Kisseberth|BMC Cancer|2017Cited by 46
Evaluation of the effects of histone deacetylase inhibitors on cells from canine cancer cell linesWilliam C. Kisseberth, Ching‐Shih Chen|American Journal of Veterinary Research|2008Cited by 30
Biological activity of dihydroartemisinin in canine osteosarcoma cell linesKenji Hosoya, William C. Kisseberth|American Journal of Veterinary Research|2008Cited by 27
Immunological responses and clinical outcomes in dogs with osteosarcoma receiving standard therapy and a Listeria vaccine expressing HER2Nicola J. Mason, Amy K. LeBlanc, Audrey Ruple et al.|Molecular Therapy|2025Cited by 10